Kacała Arkadiusz, Dorochowicz Mateusz, Korbecki Adrian, Sobański Michał, Zdanowicz-Ratajczak Agata, Patrzałek Dariusz, Janczak Dariusz, Guziński Maciej
Department of General, Interventional and Neuroradiology, Wroclaw Medical University, 50-367 Wrocław, Poland.
Department of Vascular, General and Transplantation Surgery, Wroclaw Medical University, 50-367 Wrocław, Poland.
Cancers (Basel). 2024 Dec 26;17(1):42. doi: 10.3390/cancers17010042.
Giant hepatic hemangiomas are challenging to manage, requiring effective therapeutic approaches. Transarterial bleomycin-lipiodol embolization (TACE) has shown promise as a treatment option, yet predictive factors for its success are not well defined. This study aimed to assess the efficacy of TACE for giant hepatic hemangiomas and identify factors influencing treatment outcomes. A retrospective analysis of 31 adult patients who underwent TACE with bleomycin and lipiodol between December 2014 and October 2022 was conducted. Clinical parameters including age, sex, hemangioma location, lesion size, bleomycin dose, number of TACE sessions, and follow-up duration were evaluated. The primary outcome was hemangioma volume reduction, with statistical analyses identifying factors associated with significant lesion regression. Higher bleomycin doses and longer intervals from procedure to follow-up were positively correlated with hemangioma volume reduction, while variables such as patient sex and lesion location showed no statistically significant impact on clinical success. The findings suggest that increased bleomycin dosage and extended follow-up periods may enhance treatment efficacy. The study identifies bleomycin dose and follow-up duration as predictive factors for TACE success in treating giant hepatic hemangiomas, underscoring their role in optimizing therapeutic strategies. These insights contribute to improved treatment personalization for patients with giant hepatic hemangiomas and highlight the need for further prospective studies to validate and expand upon these findings.
巨大肝血管瘤的治疗具有挑战性，需要有效的治疗方法。经动脉博来霉素-碘油栓塞术（TACE）已显示出作为一种治疗选择的前景，但其成功的预测因素尚未明确界定。本研究旨在评估TACE治疗巨大肝血管瘤的疗效，并确定影响治疗结果的因素。对2014年12月至2022年10月期间接受博来霉素和碘油TACE治疗的31例成年患者进行了回顾性分析。评估了包括年龄、性别、血管瘤位置、病变大小、博来霉素剂量、TACE疗程数和随访时间在内的临床参数。主要结局是血管瘤体积缩小，统计分析确定了与病变显著消退相关的因素。更高的博来霉素剂量和从手术到随访的更长间隔与血管瘤体积缩小呈正相关，而患者性别和病变位置等变量对临床成功没有统计学上的显著影响。研究结果表明，增加博来霉素剂量和延长随访期可能提高治疗效果。该研究确定了博来霉素剂量和随访时间是TACE成功治疗巨大肝血管瘤的预测因素，强调了它们在优化治疗策略中的作用。这些见解有助于改善巨大肝血管瘤患者的治疗个性化，并突出了进一步进行前瞻性研究以验证和扩展这些发现的必要性。
